SAN FRANCISCO – Sequenta, Inc., and its collaborators will share important data at the American Society of Hematology (ASH) annual meeting showing the sensitivity of the company’s LymphoSIGHT™ platform for the detection of minimal residual disease (MRD).
The company and multiple investigators have demonstrated that the LymphoSIGHT™ technology can measure MRD in samples in which the disease was undetectable using flow cytometry and/or polymerase chain reaction (PCR). Sequenta will make three oral and six poster presentations at ASH, scheduled for Dec. 8-11, 2012, at the Georgia World Congress Center in Atlanta.
“These presentations underscore the broad adoption of the LymphoSIGHT™ platform by the clinical research community and provide the vital clinical validation of our clinical products that will be available early next year,” said Tom Willis, CEO of Sequenta. “The presentations highlight both the technical power of the next-generation sequencing approach, as well as the breadth of its applicability to a full range of blood cancers.”
The 54th annual ASH meeting brings together the leaders in hematology, including nearly 300 pharmaceutical companies, medical suppliers, and clinical diagnostic and research-based companies to share the latest research and technology advancements in the field.
The schedule for Sequenta’s oral presentations is as follows:
Date & Time: Monday, December 10 from 7:00 a.m. to 8:30 a.m.; presentation from 7:30 a.m. to 7:45 a.m.
Session: Myeloma - Biology and Pathophysiology, excluding Therapy: Genomics
Abstract Number: 321
Title: Detection of Multiple Myeloma Cells in Peripheral Blood Using High-Throughput Sequencing Assay
Location: Thomas Murphy Ballroom 1
Collaborators: New York University, University of California San Francisco, Washington University School of Medicine
Date & Time: Monday, December 10 from 2:45 p.m. to 4:15 p.m.; presentation from 4:00 p.m. to 4:15 p.m.
Session: Adoptive Immunotherapy I
Abstract Number: 582
Title: Deep B and T Cell Repertoire Sequencing to Evaluate Minimal Residual Disease and T Cell
Responses in a Therapeutic Vaccine Trial for Mantle Cell Lymphoma
Location: C208-C210
Collaborators: Stanford University, Mt. Sinai School of Medicine
Date & Time: Monday, December 10 from 6:15 p.m. to 7:45 p.m.; presentation from 6:30 p.m. to 6:45 p.m.
Session: Non-Hodgkin Lymphoma Biology, excluding Therapy I
Abstract Number: 788
Title: Next-Generation Sequencing and Real-Time Quantitative PCR for Minimal Residual Disease (MRD) Detection Using the Immunoglobulin Heavy Chain Variable Region: A Methodical Comparison in Acute Lymphoblastic Leukemia (ALL), Mantle Cell Lymphoma (MCL) and Multiple Myeloma (MM)
Location: B313b-B314
Collaborators: University Hospital Schleswig-Holstein, Kiel, Germany, University of Torino
The schedule for Sequenta’s poster presentations is as follows:
Date & Time: Saturday, December 8 from 5:30 p.m. to 7:30 p.m.
Abstract Number: 1434
Title: ClonoSIGHT: A Standardized Clinical Assay for Measurement of Minimal Residual Disease in Leukemias and Lymphomas
Location: Hall B1-B2
Date & Time: Saturday, December 8 from 5:30 p.m. to 7:30 p.m.
Abstract Number: 1440
Title: Comparison of High-Throughput Sequencing and Flow Cytometry for Measuring Minimal Residual Disease in Pediatric Acute Lymphoblastic Leukemia: A Children’s Oncology Group Cohort
Location: Hall B1-B2
Collaborators: Children’s Oncology Group, Stanford University, University of California San Francisco, University of Washington, Johns Hopkins University, University of Florida
Date & Time: Saturday, December 8 from 5:30 p.m. to 7:30 p.m.
Abstract Number: 1388
Title: Deep Sequencing Approach for Minimal Residual Disease Detection in Acute Lymphoblastic Leukemia
Location: Hall B1-B2
Collaborators: St. Jude Children’s Research Hospital, National University of Singapore
Date & Time: Sunday, December 9 from 6:00 p.m. to 8:00 p.m.
Abstract Number: 2532
Title: Comparison of Minimal Residual Disease Detection Using High-Throughput Sequencing and Allele-Specific Oligonucleotide PCR Methods in Pediatric B-Lineage Acute Lymphoblastic Leukemia
Location: Hall B1-B2
Collaborators: Boston Children’s Hospital, Dana-Farber Cancer Institute
Date & Time: Sunday, December 9 from 6:00 p.m. to 8:00 p.m.
Abstract Number: 2666
Title: Detection of Diffuse Large B-Cell Lymphoma in Peripheral Blood Using High-Throughput Sequencing Assay
Location: Hall B1-B2
Collaborators: University of Texas MD Anderson Cancer Center
Date & Time: Sunday, December 9 from 6:00 p.m. to 8:00 p.m.
Abstract Number: 2512
Title: Minimal Residual Disease Quantification in Acute Lymphoblastic Leukemia Using High-Throughput Sequencing of Multiple Immunoreceptor Genes Predicts Relapse and Survival After Allogeneic Hematopoietic Cell Transplantation
Location: Hall B1-B2
Collaborators: Stanford University, Gregorio Marañon General University Hospital, Madrid, Spain
About Sequenta, Inc.
Sequenta is a venture backed startup dedicated to improving patient care in diseases mediated by immune cells through measurements of lymphocyte diversity. It is commercializing its LymphoSIGHT™ platform for clinical use in minimal residual disease while continuing to validate the use of its technology in a diverse set of diseases. For more information, go to www.sequentainc.com.
